Dengue Vaccines Market - Size & Upcoming Industry Trends (2024-2032)

Dengue Vaccines Market Synopsis:

Dengue Vaccines Market Size Was Valued at USD 598.10 Million in 2023, and is Projected to Reach USD 1,632.11 Million by 2032, Growing at a CAGR of 11.80% From 2024-2032.

The global Dengue Vaccines Market is projected to grow at a high rate because dengue fever has become more widespread in many countries. Dengue is an infectious disease caused by the tropical and subtropical plasmids, which are spread by mosquitoes and affect millions of people every year. This has created a lot of demand for vaccines in cases of the diseases in a bid to curb further spread and severe complications among those living in such regions. National governments, health care systems as well as vaccine producers are targeting prevention through vaccine manufacturing and deployment on this infectious disease.

Growth strategies for the dengue vaccine market are mainly based on continuous development of vaccines and growing knowledge about the disease.. Over the last few years, many new vaccines have come into production or are still in the development stage, existing as live attenuated vaccines and recombinant vaccines and designed to protect against all the four serotypes of the dengue virus. For instance, the WHO and other global health organizations are currently trying to make vaccines available especially in high risk areas and this is expected to spearhead its market growth. Further, the growth of the healthcare facilities and the increased public sector focus to prevent dengue, popularize vaccines are also the driving factors.

 Nonetheless the cost is high, availability in low-income countries is restricted, and the issue of the four serotypes in the dengue virus that requires provision of vaccines are factors which are deterring the use of dengue vaccines. stages of clinical trials, including live attenuated vaccines and recombinant vaccines, which aim to provide immunity against all four strains of the dengue virus. The World Health Organization (WHO) and other global health organizations are working to facilitate vaccine accessibility, especially in high-risk regions, further boosting market growth. Additionally, expanding healthcare infrastructure and rising government initiatives to combat dengue are contributing to the demand for vaccines.

However, challenges such as the high cost of vaccines, limited access in low-income countries, and the complexity of providing vaccines for all four dengue virus strains are inhibiting the widespread adoption of dengue vaccines. Entry barriers including, regulatory challenges, and doubt over efficacy of some of the vaccines are also limitations to market expansion. However, the market has these challenges, yet it has many opportunities for growth and development with continuous research on enhancing the vaccines’ formulation and availability. The growth of partnerships between the public and private sector and the small emerging interest in vector control and one health approaches should spur additional market expansion in the subsequent years.

Dengue Vaccines Market Trend Analysis:

Advancements in Vaccine Development and Efficacy

• Present improvements reshaping the dengue vaccine market are discussed below.. Since there are already several strong contenders- the live attenuated and the recombinant vaccines, for instance, in the advanced phases of development, the emphasis is these vaccines are effective across the dengue virus serotypes. This trend is as a result of attempts made to enhance safety profile or increase the duration of immunity offered by the vaccines. Pharmaceutical firms are consequently devoting more resources to research and innovation (R&D) in order to develop ultrasensitive, comprehensive preventive vaccines that are easy to administer and are cost effective, particularly for additional dose or one-trial vaccines to be made widely available for use across the developing world.

Public-Private Partnerships and Global Vaccination Initiatives

• • Currently, there is an emerging trend in the number of efforts being deployed in the fight against dengue fever, this is because increasing numbers of governments, global health institutions and private manufacturers of vaccines are coming forward.. The interventions like WHO’s dengue vaccination programs along with tie-ups with large-scale drug makers are making the vaccines more easily available across the affected regions especially in the low-income countries. This trend is not only providing for current exigent needs of affected populations but is also in the process of developing a sustainable disease control approach with new funding mechanisms to support development of new vaccines, regulatory and logistical infrastructure to support large-scale vaccination campaigns.

Dengue Vaccines Market Segment Analysis:

Dengue Vaccines Market Segmented on the basis of By Type, By Treatment, Route of Administration, End-Users and Distribution Channel.

By Type, Live Attenuated Vaccine segment is expected to dominate the market during the forecast period

• Dengue Vaccines Market by its type include different forms of vaccines which has their own Pros and Cons.. Examples of Live Attenuated Vaccines include some of the most frequently used everyday vaccines that provide almost full immunity through the use of a less dangerous form of virus. The Chimeric Live Attenuated Vaccines that have been developed offer cross protection by having features from different modes of dengue virus. Inactivated Vaccines employ killed virus particles and are being created to make safer versions, especially in areas with a higher proportion of stereospecific immunity to dengue. Subunit Vaccines have the virus broken down to only its components which minimizes the side effects but still elicits the body’s defenses. Last of all, Nucleic Acid-based vaccines are some of the most modern types of a versatile approach to producing the immune response by incorporating genetic material into host cells to synthesize the necessary virus proteins. In other words, each type of vaccine will address another area of interest among dengue immunities such as safety, effectiveness and lifespan of the vaccines and more research is being conducted in an effort to try to come up with better solutions to the problem taking into consideration the world’s need.

By End-Users, Hospitals segment expected to held the largest share

• The primary stakeholders of dengue vaccines normally encompass hospitals, homecare settings, specialty clinics as well as other healthcare centers.. Hospitals are the leading end-users due to their ability to give long arms jab to many patients especially during an outbreak. Another vital factor in the vaccine administration is specialty clinics that work on infectious diseases particularly in center of dengue breakout. Homocare locations are emerging as an important segment because more patients are now demanding vaccinations in a comfortable and more personalised way. Other end-users include public health organisations, governmental vaccination programmes and mobile health clinics that support mass vaccination in endemic regions. When vaccination supply increases, a wide array of these facilities will play a more definitive part in providing the dengue vaccines to those who need it most.

North America is Expected to Dominate the Market Over the Forecast period

• North America is expected to emerge as the largest market for dengue vaccines within the upcoming years due to strong healthcare, leading pharma companies, and large investors in vaccine development.. As the knowledge of threatening new vector-borne diseases spreads, both federal and local authorities, and healthcare organizations in North America are investing in the dengue vaccine. The market is also backed by major pharma medial players like Pfizer and Merck with significant investments in clinical and partnership for dengue vaccine development. Also, increasing awareness of people towards disease transmission, especially in regions where there is high permeability to regions with a high prevalence of such diseases will also continue to propel the market forward in North America.

Active Key Players in the Dengue Vaccines Market:

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• BIO-MED (India)
• Intercept Pharmaceuticals, Inc. (U.K.)
• Emcure Pharmaceuticals Ltd (India)
• Changchun BCHT Biotechnology Co. (China)
• Novo Medi Sciences Pvt. Ltd. (India)
• Other Active Players